News & Updates
  • Home
  • About Us
  • Contact
  • Home 1
  • News & Updates

    Patented New ISO Name Approved – December 2025: Triflupyroxazin, A New N-phenylimide Herbicide From Liaoning Cynda Chemical Co., Ltd.

    Patented New ISO Name Approved – December 2025: Amfenamacril, A New Aminocyanoacrylate Fungicide From Jiangsu Pesticide Research Institute Co., Ltd.

    Delhi HC refuses FMC’s plea to stop Natco’s Cyantraniliprole commercialization

    Chlorantraniliprole Patent Litigation Outcome – Best Agrolife Ltd. & Natco to become First Indian Companies to launch Indigenously Manufactured Chlorantraniliprole (CTPR)

    adminSeptember 21, 202205.6k views

    Best Agrolife Ltd. & Natco to become the First Indian Company to launch Indigenously Manufactured Best Agrolife Ltd Chlorantraniliprole CTPR technology is…

    Read more

    WHO Grants Prequalification to GSK’s Mosquirix – the first and only approved Malaria Vaccine

    adminSeptember 20, 202201.7k views

    Summary: The World Health Organization (WHO) has awarded prequalification to Mosquirix, GSK’s malaria vaccine. This is the first prequalification for a malaria vaccine…

    Read more

    bluebird bio Receives FDA Accelerated Approval for SKYSONA®(elivaldogene autotemcel)Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)

    adminSeptember 19, 202203k views

    Synopsis: SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys with this devastating and…

    Read more

    Mallinckrodt Receives U.S. FDA Approval for Terlivaz® (Terlipressin) for Injection for the Treatment of Hepatorenal Syndrome (HRS)

    adminSeptember 16, 202201.6k views

    Highlights: Terlivaz is the first and only FDA-approved treatment for adults with HRS involving rapid reduction in kidney function. Terlivaz is expected…

    Read more

    For $1.1 Billion, Novo Nordisk To Buy Forma Therapeutics

    adminSeptember 12, 202201.9k views

    Synopsis: On September 1, 2022, Novo Nordisk and Forma Therapeutics revealed that Novo Nordisk would buy Forma Therapeutics for for $1.1 billion.…

    Read more

    Spectrum Pharmaceuticals Receives FDA Approval for ROLVEDON™ (eflapegrastim-xnst) Injection

    adminSeptember 10, 202201.8k views

    Summary: First novel Long-Acting GCSF (LA-GCSF) product approved in over 20 years ROLVEDON™ developed using proprietary LAPSCOVERY™ technology with a differentiated molecular structure and…

    Read more

    Bristol Myers Squibb Notches another FDA Approval for Sotyktu™ (Deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis

    adminSeptember 10, 202203.2k views

    Highlights:  Bristol Myers Squibb’s Sotyktu, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the only approved TYK2 inhibitor worldwide and the…

    Read more

    QOL Medical, LLC receives FDA approval of Sucraid® (Sacrosidase) Oral Solution single-use containers for Patients with Congenital Sucrase-Isomaltase Deficiency (CSID)

    adminSeptember 8, 202202.1k views

    QOL Medical, LLC, a ground-breaking, rare disease pharmaceutical company, announced today that the United States (U.S.) Food & Drug Administration (FDA) approved Sucraid® single-use containers…

    Read more

    Vertex Announces U.S. FDA Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to 24 months

    adminSeptember 5, 202202.3k views

    Summary: Orkambi was first approved in 2015 in the US and is now available in more than 30 countries.  Vertex Pharmaceuticals Incorporated…

    Read more

    Boehringer’s Spevigo (spesolimab) Bags First FDA Approval for Rare Skin Disease, for Generalized Pustular Psoriasis (GPP)

    adminSeptember 5, 202201.6k views

    Synopsis: German drugmaker Boehringer Ingelheim has its first regulatory approval for spesolimab, its antibody therapy for rare and life-threatening skin disorder generalised…

    Read more

    Posts navigation

    1 … 14 … 105
    View Desktop Version

    Powered by PenciDesign

    Back To Top